Overview: Niemann-Pick Disease Quantitative TestIntroduction: The Niemann-Pick Disease Quantitative Test measures enzyme activity to diagnose Niemann-Pick disease, causing liver or neurological issues. Aligned with 2023 NORD guidelines, it uses quantitative assay for high specificity, supporting metabolic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected Niemann-Pick disease types A, B, or C.
Other Names: Niemann-Pick Assay, Sphingomyelinase Activity Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Niemann-Pick testing began in the 1960s with lysosomal storage research. Quantitative assays improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures sphingomyelinase activity to diagnose Niemann-Pick disease, guides treatment, and evaluates patients with liver or neurological issues.
Test Parameters: 1. Sphingomyelinase Activity
Pretest Condition: No fasting required. Collect whole blood or fibroblasts. Report history of liver issues, neurological issues, or developmental delays.
Specimen: Whole Blood (EDTA, 2-5 mL), Fibroblasts (sterile container, 0.5-2 cma³). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document liver issues, neurological issues, splenomegaly, or family history of lysosomal storage diseases. Include current medications, especially enzyme replacement therapy.
Consent: Written consent required, detailing the tests purpose, Niemann-Pick disease implications, and risks of sample collection.
Procedural Considerations: Uses quantitative assay to measure sphingomyelinase activity in specimens. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for Niemann-Pick diagnosis.
Factors Affecting Result Accuracy: Improper sample storage or low cell viability can affect results. Contamination may reduce specificity.
Clinical Significance: Reduced sphingomyelinase activity confirms Niemann-Pick disease (types A or B), guiding supportive care or transplant evaluation. Normal activity may require NPC gene testing.
Specialist Consultation: Consult a geneticist or metabolic specialist for result interpretation and treatment planning.
Additional Supporting Tests: NPC1/NPC2 gene sequencing, filipin staining, or liver biopsy to confirm Niemann-Pick diagnosis.
Test Limitations: Not diagnostic for type C; clinical correlation is needed. Sample quality affects sensitivity.
References: NORD Niemann-Pick Guidelines, 2023; Journal of Inherited Metabolic Disease, Patterson MC, 2022.
